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Abstract: Duchenne muscular dystrophy (DMD) is an X-linked, progressive muscle-wasting
disease caused by mutations in the DMD gene. Since the disease was described by physicians in the
19th century, information about the subject has been accumulated. One author (Sugita) was one of
the coworkers who ﬁrst reported that the serum creatine kinase (CK) level is elevated in progressive
muscular dystrophy patients. Even 50 years after that ﬁrst report, an elevated serum CK level is still
the most useful marker in the diagnosis of DMD, a sensitive index of the state of skeletal muscle, and
useful to evaluate therapeutic eﬀects. In the latter half of this article, we describe recent progress in
the therapy of DMD, with an emphasis on gene therapies, particularly exon skipping.
Keywords: Duchenne muscular dystrophy, dystrophin, exon skipping, out-of-frame
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Introduction
Muscular dystrophy is not a single disease but a
group of genetically heterogeneous muscle diseases
marked by progressive wasting and weakness of the
skeletal muscles, and sometimes involvement of
cardiac and smooth muscle or other tissues. In
1851, Meryon reported boys with symptoms consis-
tent with the diagnosis of muscular dystrophy,1) and
in 1868 in France, Duchenne published a detailed and
systematic clinical, muscle pathological, and electro-
physiological study of an “atrophie musculaire pro-
gressive”, which is now generally recognized as
Duchenne muscular dystrophy (DMD).2) Its preva-
lence in the population is estimated to be 1.8–4.8 per
100,000. Although the gene responsible was identiﬁed
in 19863),4) and the underlying pathogenesis is
understood to some extent,5) there is no eﬀective
therapy at present other than corticosteroids. In this
article, we review historical aspects of the research on
DMD and discuss the therapies of the near future.
Biochemistry and diagnosis of DMD
Biochemical abnormalities in patients with
muscular dystrophy were ﬁrst reported by Sibley
and Lehninger in 1949.6) They determined serum
aldolase activity in patients with muscular dys-
trophy, and reported increased serum aldolase
activity in the patients. Sugita measured the serum
aldolase levels of patients and conﬁrmed that
patients with muscular dystrophy had elevated
serum aldolase activity; this ﬁnding was reported in
a Japanese journal in 1958.7) At the end of the same
year, a middle-aged male was hospitalized at the
University of Tokyo Hospital directed by Prof. Dr.
Shigeo Okinaka. The patient had moderately atro-
phic extremities without positive tendon reﬂexes.
Curiously, he did not show any sensory disturbance.
Interestingly enough, he had a markedly elevated
serum aldolase level. After much deliberate consid-
eration, Prof. Okinaka diagnosed him with a motor
neuronitis, however, at grand rounds, the attending
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suﬀering from muscular dystrophy, based on the
serum aldolase activities that Sugita measured. Prof.
Okinaka became furious and told Sugita that it was
not acceptable to make a diagnosis simply on the
determination of something in the blood. In retro-
spect, Prof. Okinaka was correct; the patient was
probably suﬀering from polymyositis rather than
muscular dystrophy.
However, the incident led to one of the
monumental achievements in the history of muscular
dystrophy research due to the outstanding profes-
sional intuition of Dr. Setsuro Ebashi. When Dr.
Momoi, a close friend of Dr. Ebashi since middle
school, told him about the serum aldolase activity in
muscular dystrophy, he pointedly asked Dr. Momoi,
“Why do you determine a nonspeciﬁc enzyme such as
aldolase in muscular diseases? You should look at the
level creatine phosphokinase, which is more speciﬁc
to skeletal muscle than aldolase.” It was a stroke of
genius! At his suggestion, we set up a team, headed
by Dr. Ebashi and including Drs. Momoi, Toyokura,
and Sugita, to study creatine phosphokinase (CPK; it
was also known as creatine kinase or CK). Thus, ﬁrst
paper on serum CK activity in progressive muscular
dystrophy was published by Ebashi and coworkers in
1959.8) Among various neuromuscular disorders, they
found increased serum CK levels in patients with
muscular dystrophy, and it is now regarded as the
most reliable laboratory test for muscular dystrophy.
The discovery of the importance of serum CK opened
the door for the recent myology research, in
particular pathological studies including genetics
and the exploration of treatments such as gene
therapy.
Discovery of dystrophin and its localization
at the muscle surface membrane
A pioneer application of positional cloning to
human diseases appeared in 1986, when the gene
responsible for DMD/Becker muscular dystrophy
(BMD) was isolated by Dr. A.P. Monaco et al. of Dr.
L. Kunkel’s group.3) The DMD gene is 2,500kb long
and consists of 79 exons covering 1% of the x-
chromosome. It is transcribed to yield a 14kb cDNA.
In 1987, Dr. E.P. Hoﬀman et al. identiﬁed a 427kD
protein encoded by the DMD gene, and this protein
was named “dystrophin”,4) which is absent from the
skeletal muscle of most patients with DMD. Almost
all cases of DMD showed an out-of-frame mutation.
In contrast, most patients with BMD had an in-frame
mutation. Using polyclonal antibodies against the
near N-terminal portion derived from the dystrophin
cDNA, Dr. Kiichi Arahata et al. of the muscular
dystrophy research group at National Institute of
Neuroscience, National Center of Neurology and
Psychiatry, Japan, identiﬁed a speciﬁc immunohis-
tochemical reaction with peptides on the surface
membrane of skeletal and cardiac muscle ﬁbers that
was absent in the muscles of DMD patients.9) These
results have been conﬁrmed by other research groups.
In symptomatic carriers of DMD, a distinct mosaic
pattern of immunohistochemical staining of the
surface membrane of the muscle ﬁbers can be
observed. BMD exhibits a positive but faint and
patchy expression pattern of dystrophin with altered
protein contents and molecular weights. Thus, it
became clear that DMD and BMD are caused by
fragility of the muscle surface membrane due to the
lack of dystrophin.
Development of therapy for DMD
Drug treatment for DMD patients is currently
restricted almost completely to corticosteroids (ox-
androlone and prednisone), but a variety of ther-
apeutic approaches to muscular dystrophies have
been tested over the past few decades, and some of
them show great promise (recently reviewed in
Ref. 10, and current situation was summarized in
Table 1). For successful application of viral vector-
mediated gene therapy, there are still several hurdles
to be overcome.11) Pluri- or multipotent stem cell-
based therapies are still in their immature stages, but
currently some alternatives are progressing to clinical
trials. Among several therapeutic approaches in
preclinical or clinical stage, authors here focus on
one of the most promising therapeutic approaches:
exon skipping with antisense oligonucleotides (AOs).
Exon-skipping therapy using AOs
DMD is caused by the lack of dystrophin, most
commonly as a result of frame-shift mutations.
Deletions and duplications in the DMD gene result
in out-of-frame mRNA, such as nonsense mutations
in which a single base change alters a codon into a
premature stop codon. Theoretically, in these cases,
selective removal of the ﬂanking exons can result in
an in-frame mRNA transcript. Such an in-frame
mRNA transcript can be translated into a quasi-
dystrophin protein (reviewed in Ref. 12). AOs, which
hybridize the sequences near the splice acceptor or
donor sites as well as within exons, can alter gene
expression via steric block interference with the
splicing machinery, and thereby direct the exclusion
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in restoration of the reading frame of dystrophin
mRNA and the expression of a shorter, truncated but
functional dystrophin.
One of the pioneering researchers who tried to
restore the reading frame of the mutated DMD
transcripts was Dr. Masafumi Matsuo at Kobe
University.13) His group tried to skip exon 19 of the
DMD gene in exon 20-deleted DMD patients, based
on the idea of DMD Kobe, where exon 19 has been
skipped due to a 52-bp deletion within the exon.
Later, proof-of-concept studies by many groups
followed in vitro and in vivo (reviewed in Ref. 14).
Chemistries of AOs
For maximal eﬀects in exon-skipping therapy,
the chemistry of AOs seems to be one of most critical
factors. AOs used for exon skipping are usually 20–25
bases long and chemically synthesized. Various
chemistries for AOs have been proposed to overcome
the unstable nature of single-strand DNA or RNA
molecules. Several modiﬁcations of AOs include
bicyclic locked nucleic acid (LNA), peptide nucleic
acid (PNA), ethylene-bridged nucleic acid (ENA), 2′-
O-methyl phosphorothioate AO (2′-O-MePS AO),
and phosphorodiamidate morpholino oligomer
(PMO). Among them, 2′-O-MePS AO and PMO
are the most frequently utilized because of their
suitable properties (Fig. 1).
2′-O-MePS AO. The structure of 2′-O-MePS
AO is similar to that of RNA, but it is methylated
at the 2′-OH position of the ribose ring. 2′-O-MePS
AO is widely used because it is relatively easy to
synthesize and cheap to produce. 2′-O-MePS AO is
stable, has a high aﬃnity to mRNA, and is also
resistant to nucleases, however the low solubility of
2′-O-MePS AO in water prevents its use at higher
dosages.
PMO. PMO has a morpholine ring instead of a
deoxyribose ring in DNA, and these artiﬁcial rings





Drug MYO-029 Completed; not eﬀective
Read-through
PTC124 Completed; not eﬀective
Gentamicin Completed; not eﬀective
Others
Pentoxifylline Completed; not eﬀective
Idebenone Phase III
Ramipril vs. Carvedilol Phase IV
Coenzyme Q10 and prednisone Phase III
Coenzyme Q10 and lisinopril Phase II/III
Debio-025 (cyclosporine analogue) Phase IIb
Exon skipping (systemic delivery)
Gene therapy PRO051 (2′-O-MePS AO)(exon 51 skipping) Phase III
PRO044 (2′-O-MePS AO)(exon 44 skipping) Phase I/II
AVI-4658 (PMO)(exon 51 skipping) Phase IIb
AAV vector
rAAV2.5-CMV-Mini-Dystrophin Phase I*
Satellite cells (myoblasts) Pending
Cell therapy Mesoangioblasts In preparation
Induced pluripotent stem (iPS) cells Experimental
Shown are representative ongoing or just ﬁnished clinical trials for DMD. Some have ﬁnished with disappointing results.
For more information, please refer to the homepage presented by the U.S. National Institute of Health,
‘ClinicalTrials.gov’.
*Unwanted immune responses to dystrophin have been reported at the 2010 meeting of the American Academy of
Neurology (http://quest.mda.org/news/caution-immune-response-seen-dmd-gene-therapy).
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date, enabling highly sequence-speciﬁc, stronger base
pairing to the target RNA than RNA or DNA.
Importantly, PMO does not stimulate or activate
Toll-like receptors and therefore does not activate
innate immune responses. In addition, PMO is
believed to be not recognized by cellular proteins
and to be resistant to nuclease-mediated degradation.
PMO has high solubility in water.
Other chemicals to improve eﬃciencies of
delivery to whole-body musculature. Delivery of
AOs to normal tissues in vivo is generally diﬃcult
because healthy tissues do not take up PMO or 2′-O-
MePS AO. Although the mechanisms are not fully
understood, PMO can easily enter the nuclei of
skeletal muscle of DMD patients. This might be
because the dystrophin-deﬁcient muscle membrane is
inherently leaky due to absence of the dystrophin-
glycoprotein complex.
However, systemic administration of 2′-O-MePS
AO or PMO failed to restore dystrophin expression in
the heart, although it is again unclear why cardiac
cells do not take up 2′-O-MePS AO or PMO. To
improve the eﬃcacy of its introduction into cardio-
myocytes, a PMO covalently conjugated with a
designed cell-penetrating peptide (PPMO) was in-
jected into dystrophin-deﬁcient mdx mice. Systemic
delivery of the novel PPMO restored dystrophin to
almost normal levels in both cardiac and skeletal
muscles in mdx mice.15) Later, the same group
reported that a PMO modiﬁed with an octaguanidi-
nium dendrimer, Vivo-Morpholino, also restored
dystrophin expression in cardiac and skeletal
muscles.16) So far, no study has clearly demonstrated
toxicity after systemic delivery or immune response
to PPMO or Vivo-Morpholino.
AOs designs
To obtain eﬃcient exon skipping while lowering
the dose of AOs for clinical trials, the design of the
AOs (base sequence) is important. In eukaryotic
organisms, the gene is transcribed in the nucleus and
introns are spliced out into mRNA, and then the
mRNA is exported from the nucleus to the cyto-
plasm. Therefore, AOs must either enter the nucleus,
where they bind to their target pre-mRNA sequences
and get in the way of molecules that are otherwise
involved in the splicing process, or they must alter
the secondary structure folding of the pre-mRNA.
AOs targeting exon-intron boundary sequences can
often eﬀectively induce exon skipping. On the other
hand, when web-based software, such as ESEﬁnder
(http://rulai.cshl.edu/tools/ESE), is used to design
AO sequences to target an ESE, exon skipping is not
always induced. Recently, Wee et al. have developed
bioinformatic tools to optimize AOs sequences based
on the pre-mRNA secondary structure.17) Never-
theless, no single design tool is suﬃcient for designing
the AOs, and often empirical analysis is required.
Proof of principle of exon skipping therapy
in animal models
Cultured skeletal muscle cells from DMD pa-
tients are often used to evaluate the exon-skipping
eﬃciency of newly-designed AOs.18) However, to
assess the therapeutic beneﬁts, preclinical studies
must be performed using animal models. In this
section, studies using mdx mice and dystrophic dogs
are described and discussed.
Exon skipping in mdx mice. The mdx mouse
is a naturally occurring animal model that has a
nonsense mutation in exon 23 of the DMD gene,
resulting in a premature stop codon and complete
absence of dystrophin.19) Mdx mice show high levels
of serum CK, active muscle degeneration/regener-
ation cycles, and loss of myoﬁbers and ﬁbrosis in the
diaphragm, but still show mild, non-progressive
muscle weakness of the limbs and only 20% reduction
in life span. In this point, mdx might not be an ideal
animal model for DMD, but due to the low cost of
maintenance and short gestation times, many pre-























Fig. 1. Comparison of chemistry used in clinical trials. 2′-O-
MePS AO: 2′-O-methyl phosphorothioate antisense oligonucleo-
tides. PMO: phosphorodiamidate morpholino oligomers. PMO
(AVI BioPharma, http://www.avibio.com/) has a diﬀerent back-
bone (morpholino backbone) from RNA or DNA, enabling
highly sequence-speciﬁc, stronger base pairing to the target RNA
than RNA or DNA. Red highlights the diﬀerences in the
chemistry from RNA or DNA.
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the AOs with the non-ionic polymer F127, which
promotes intracellular uptake of 2′-O-MePS AO, to
the skeletal muscles of 2-week-old mdx mice. The
result showed that dystrophin together with --
dystroglycan, sarcoglycans, and nNOS was restored
in 20% of the muscle ﬁbers.20) Furthermore, systemic
administration of anti-sequences of the same 2′-O-
MePS AO with F127 revealed that dystrophin was
expressed in the skeletal muscle of the whole body. 2′-
O-MePS AO produced no toxicity, but its expression
did not reach a therapeutic level.21) Likewise, Wells
et al. reported that local administration of 2′-O-
MeAO using electroporation restored dystrophin
expression to up to 20% of the normal level.22)
Systemic induction of dystrophin expression by
PMO administration reached up to 20% in whole
body skeletal muscle.23)
Dystrophic dogs as models for DMD.
Muscular dystrophy in dogs was originally identiﬁed
in golden retrievers and designated “golden retriever
muscular dystrophy” (GRMD). GRMD shows pro-
gressive skeletal muscle weakness and atrophy as well
as abnormal electrocardiographic ﬁndings and my-
ocardial ﬁbrosis like those seen in DMD. Because the
phenotype and genetic background are closer to
human DMD than those of the mouse model, the
dystrophic dog is a useful model to examine patho-
genesis and therapeutic strategies. However, the dogs
are too large to be maintained conveniently; thus, we
have established a colony of medium-sized beagle-
based dystrophic dogs (canine X-linked muscular
dystrophy in Japan: CXMDJ) at the National Center
of Neurology and Psychiatry, Tokyo, by using
artiﬁcial insemination of frozen GRMD semen.24)
Still, we have found that CXMDJ requires extra
daily care, and therefore, is expensive.
Clinical features of CXMDJ. The level of
serum CK in neonatal CXMDJ is very high, and 25–
33% of the pups die of respiratory failure during the
neonatal period, mainly due to severe degeneration
and thus dysfunction of the diaphragm. Around the
age of 2–3 months, atrophy and weakness of limb
muscles appear; then, gait disturbance, joint con-
tracture, macroglossia, and dysphasia appear in rapid
progression until the dogs are 10 months of age;
subsequently, the progression is retarded.24)
Cardiac involvement of dystrophic dogs.
Dystrophic dogs and DMD have similar cardiac
involvement, including distinct deep Q-waves on
the electrocardiogram and ﬁbrosis of the left ven-
tricular wall. The distinct deep Q-waves are generally
ascribed to ﬁbrosis in the posterobasal region of the
left ventricular wall in DMD, but one report suggests
that the deep Q-waves precede the development of
ﬁbrosis in CXMDJ.25) Importantly, Purkinje ﬁbers in
dystrophic dogs showed remarkable vacuolar degen-
eration despite the absence of detectable ﬁbrotic
lesions in the ventricular myocardium. In the
degenerated Purkinje ﬁbers, Dp71, a C-terminal
truncated isoform of dystrophin, was up-regulated
at the sarcolemma. In addition, the calcium-depend-
ent protease 7-calpain was found at the cell periphery
near the sarcolemma or in the vacuoles. Utrophin,
a homologue of dystrophin, was also highly up-
regulated in the Purkinje ﬁbers in the early stage.
Together, the selective degeneration of Purkinje
ﬁbers may be associated with distinct deep Q-waves
on electrocardiograms and the fatal arrhythmia seen
in dystrophinopathy.25)
Multi-exon skipping in dystrophic dogs. The
dystrophic dogs have a point mutation at the intron
6 splice acceptor site in the canine DMD gene,
resulting in skipping of exon 7 and a premature stop
codon in exon 8. Thus, dystrophin is not produced in
the aﬀected dog. Recently, Yokota et al. reported
systemic administration of three PMOs targeting
exons 6 and 8 to convert an out-of-frame mutation
to an in-frame mutation in CXMDJ.26) The result
showed that dystrophin was restored in the entire
body skeletal muscle. The authors reported that the
motor ability of treated dystrophic dogs was im-
proved and that they showed no side eﬀects. To the
best of our knowledge, this is the ﬁrst report that
multi exon-skipping is feasible and eﬀective in
improving performance of dystrophic animals in vivo.
As reported in mdx mice, a combination of
PMOs failed to restore the expression of dystrophin
in cardiac muscle, even at a high dose in CXMDJ.T o
resolve this problem, modiﬁed PMOs (PPMO or
Vivo-Morpholino) were tested (Yokota et al., un-
published observation).
Viral vector-mediated exon skipping
The duration of the eﬀects of AOs in vivo is
limited; therefore, patients have to be injected with
AOs weekly or monthly to maintain the therapeutic
levels of dystrophin. An alternative strategy is to
deliver AOs via adeno-associated virus (AAV)
vector-mediated gene transfer. Based on an AAV
vector-mediated approach, Goyenvalle et al. linked
U7 small nuclear RNA to antisense sequences to
achieve sustained dystrophin expression derived from
skipped mRNA for more than 13 weeks in the limbs
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to modify muscle stem cells expressing modiﬁed small
nuclear RNAs that change splicing patterns of pre-
mRNAs and correct the reading frame.28),29)
Test of AOs eﬃcacy using patient cells
To apply exon skipping therapy to individuals,
not only the deletion pattern in the genome but also
the mRNA/cDNA level must be analyzed to
determine the precise splicing pattern and to design
therapeutic AOs. Subsequently, designed AOs must
be tested in vitro on cells derived from the patient
before clinical trials. Skin ﬁbroblasts are easy to
obtain, but the levels of DMD transcripts are low,
and therefore the results tend to be variable. On the
other hand, preparation of myoblasts through biopsy
from dystrophic patients is invasive. Therefore,
transformation of ﬁbroblasts to myoblasts in vitro
by forced MyoD expression is often used to test the
eﬃcacy of AOs.30),31)
Multiple exon skipping: theory and reality
We and other research groups tried to ﬁnd the
most eﬀective target of exon skipping strategy among
DMD patients. Theoretically, exon 51-skipping
therapy is eﬀective for up to 15% of DMD patients
having a deletion, but large numbers of DMD
patients will not beneﬁt from it. We recently reported
that three unrelated patients with a deletion of exons
45–55 showed very mild skeletal muscle involvement
and were ambulant until his seventies in a patient.32)
Béroud et al. also described 15 asymptomatic or very
mild patients with an exon 45–55 deletion.33) In fact,
the Leiden Muscular Dystrophy database indicates
that the exon 45–55 deletion produced a BMD
phenotype in more than 95% of the cases. Collec-
tively, these observations indicate that approxi-
mately 60% of DMD patients having a deletion
within the hot spot may be treatable with multi-exon
skipping of exons 45–55. We recently tried exon 45–
55 skipping by injection of a mixture of 10 PMOs
in the anterior tibial muscle of mdx52 mice34) and
conﬁrmed that multi-exon skipping is feasible, at
least in mice (Aoki et al., unpublished observation).
However, the eﬃcacy of multi-exon skipping was
lower than that of single-exon skipping, possibly
because many partially spliced products, many of
which are again out-of-frame, are produced.
Phase I/II clinical trials of exon skipping
for DMD
Based on the success of AOs-mediated exon
skipping in animal models, clinical trials have been
performed or are in progress for the skipping of exon
51 of the DMD gene (Fig. 2 and Table 1).
2′-O-MePS AO. Skipping of the exon 51 of the
DMD gene with 2′-O-MePS AO, PRO051, has been
already tested on DMD patients by a Dutch group.35)
Dystrophin pre-mRNA (normal)
46 47 49 48 51 50 52
46 47 49 48 51 50 52
46 47 49 48 51 52
out-of-frame
Dystrophin pre-mRNA (deletion of exon 50)
46 47 49 48 51 50 52
46 47 49 48 52
Dystrophin pre-mRNA +AO







46 47 49 48 51 50 52
Fig. 2. Example of exon skipping therapy for DMD patients with deletion of exon 50. A. Normal dystrophin transcript and mRNA.
B. Deletion of exon 50 disrupts the open reading frame, leading to a premature stop codon, unstable mRNA, and a truncated unstable
protein. C. Targeted skipping of exon 51 using antisense oligonucleotides, such as AVI-4658 or PRO051 (blue line), restores the
reading frame and produces a truncated but functional dystrophin that lacks exons 50 and 51.
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PRO051 injected into the tibialis anterior muscle. A
biopsy performed 28 days later revealed restoration
of sarcolemmal dystrophin in 64% to 97% of
myoﬁbers of each patient. Further, PRO051 did not
evoke any clinically apparent adverse events.
PMO. Recently, a UK group reported that
local injection of morpholino oligomer AVI-4658
successfully restored the expression of dystrophin in
treated muscles of all seven DMD patients.36) No
adverse events related to AVI-4658 were observed.
Based on these observations, systemic injection of
AVI-4658 (Phase I and IIa) is now ongoing in the
UK. At present, a Good Manufacturing Practice
grade of PMO is produced exclusively by AVI
Biopharma Inc. (http://www.avibio.com/).
Conclusions
Since the identiﬁcation of dystrophin in 1987,
various therapeutic approaches to DMD treatment
have been evaluated, and now exon skipping, which
is one of the most promising strategies, is in clinical
trials. Because individual DMD patients have diﬀer-
ent mutations, exon skipping therapy requires a
precise evaluation of mutations in the genome and
the cDNA, and splicing patterns must be conﬁrmed
in each patient’s muscle. In this point, exon skipping
is a quite new, personalized therapeutic strategy. As
clinicians and researchers involved in the study of
muscular dystrophies, one of us for more than 50
years, we are pleased with recent progress in the ﬁeld
and hope that DMD patients beneﬁt from this new
therapy in the near future.
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discovered the increase in serum creatine kinase (CK) in muscular dystrophy. Even now,
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of muscular dystrophy. In 1988, his research group at the National Institute of
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the surface membrane of the skeletal and cardiac muscles and absent in DMD muscles.
He was promoted to Director General of the Institute in 1989 and devoted himself to the
progress of neuroscience research, health and welfare of the patients suﬀering from mental, neurological and
developmental disorders. He was awarded Uehara Prize in 1986 and The Takeda Prize for Medical Science in 1996.
He was installed as the President of NCNP in 1994 and retired in 1998. Since 2009, he is the President of Japan
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